The Role of Interleukin-20 in Paclitaxel-Associated Peripheral Neuropathy in Non-Metastatic Breast Cancer Patients Receiving Chemotherapy

Basit Öğe Kaydı
dc.authoridCELIKKOL, ALIYE/0000-0002-3799-4470
dc.authoridCavdar, Eyyup/0000-0001-5885-3047
dc.authoridSEBER, SELCUK/0000-0001-9081-2405
dc.authoridiriagac, Yakup/0000-0001-7411-1705
dc.authoridKaraboyun, Kubilay/0000-0002-1783-8075
dc.contributor.authorKaraboyun, Kubilay
dc.contributor.authorCavdar, Eyyup
dc.contributor.authorIriagac, Yakup
dc.contributor.authorYilmaz, Ahsen
dc.contributor.authorCelikkol, Aliye
dc.contributor.authorAvci, Okan
dc.contributor.authorSeber, Erdogan Selcuk
dc.date.accessioned2024-10-29T17:59:33Z
dc.date.available2024-10-29T17:59:33Z
dc.date.issued2023
dc.departmentTekirdağ Namık Kemal Üniversitesi
dc.description.abstractIntroduction: This study investigated the relationship between serum interleukin-20 (IL-20) levels and paclitaxel-associated neuropathy in patients with non-metastatic breast cancer. Paclitaxel-induced peripheral neuropathy (PIPN) is a significant side effect of paclitaxel chemotherapy, and the exact mechanism underlying PIPN is not fully understood. Methods: This prospective observational study was conducted with non-metastatic breast cancer patients between January 2022 and November 2022. Neuropathy symptoms were evaluated using the QLQ-CIPN20 questionnaire, and serum IL-20 levels were measured at three time points: before chemotherapy, on the 7(th) day after the first paclitaxel treatment, and after the last treatment. Univariate and multivariate logistic regression analyses were performed to identify factors predicting PIPN. Results: This study was completed with 59 female patients. During the study, 47 patients (79.6%) reported any degree of neuropathy, whereas 12 patients (20.4%) had no neuropathy. Univariate analysis to predict neuropathy measured on day 7 after first paclitaxel administration demonstrated that age, body mass index, 7(th)-day serum IL-20 level, and last cycle serum IL-20 level were predictive for PIPN. Conclusion: This study demonstrated the relationship between serum IL-20 levels and paclitaxel-related neuropathy in breast cancer patients. Further research targeting the function of IL-20 is needed to investigate potential strategies to prevent and treat PIPN.
dc.identifier.doi10.4274/imj.galenos.2023.59908
dc.identifier.endpage339
dc.identifier.issn2619-9793
dc.identifier.issn2148-094X
dc.identifier.issue4en_US
dc.identifier.startpage334
dc.identifier.trdizinid#BAŞV!
dc.identifier.urihttps://doi.org/10.4274/imj.galenos.2023.59908
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1243661
dc.identifier.urihttps://hdl.handle.net/20.500.11776/14771
dc.identifier.volume24
dc.identifier.wosWOS:001111211400002
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.publisherGalenos Publ House
dc.relation.ispartofIstanbul Medical Journal
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectPaclitaxel
dc.subjectperipheral neuropathy
dc.subjectbreast cancer
dc.subjectIL-20
dc.subjectQLQ-CIPN20
dc.titleThe Role of Interleukin-20 in Paclitaxel-Associated Peripheral Neuropathy in Non-Metastatic Breast Cancer Patients Receiving Chemotherapy
dc.title.alternativeThe Role of Interleukin-20 in Paclitaxel-Associated Peripheral Neuropathy in Non-Metastatic Breast Cancer Patients Receiving Chemotherapy
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu